Objective-ABCA1 mediates cellular cholesterol and phospholipid efflux to apolipoprotein A-I and other apolipoprotein acceptors. In this study, we analyzed the effect of the immunosuppressant cyclosporin A on the ABCA1-mediated lipid effluxes reactions. Methods and Results-Cyclosporin A acted as a potent inhibitor of ABCA1 activity in several cell lines. Using the RAW264.7 mouse macrophage cell line, in which ABCA1 and its associated cholesterol efflux activity are inducible by cAMP analogues, cyclosporin A inhibition of cholesterol efflux to apolipoprotein A-I was rapidly reversible after its removal from the culture media, implying that ABCA1 levels were not drastically reduced by cyclosporin A. In fact, cyclosporin A treatment decreased ABCA1 turnover and yielded a 2-fold increase in cell-surface ABCA1. Despite the increase in cell-surface ABCA1, cyclosporin A decreased apolipoprotein A-I uptake, resecretion, and degradation in RAW cells. Finally, consistent with the inhibition of ABCA1 in vitro, cyclosporin A treatment induced a 33% reduction of high-density lipoprotein (HDL) levels in mice. Key Words: macrophage Ⅲ cholesterol Ⅲ high-density lipoprotein H igh plasma high-density lipoprotein (HDL) levels are associated with a decreased incidence of atherosclerosis. This anti-atherogenic property of HDL is probably mediated in part by its capacity to remove excess cholesterol from foam cells. The ATP-binding cassette transporter ABCA1, which mediates cholesterol and phospholipid efflux to lipid-poor HDL apolipoproteins, plays a key role in the elimination of cholesterol from macrophages in the artery wall. Mutations in ABCA1 cause Tangier disease, a disorder characterized by very low HDL levels, cholesterol deposition in macrophages, and premature atherosclerosis. Macrophage ABCA1 has specifically been shown to have an anti-atherogenic role in mouse models of atherosclerosis, as observed in bone marrow transplantation studies in which ABCA1-deficient marrow donors led to larger aortic lesions than wild-type donors. 1, 2 Macrophage ABCA1 expression is highly regulated, and its transcription is markedly increased by cholesterol loading via the nuclear liver X receptor and retinoic X receptor, 3 and in rodent cells by analogs of cAMP through an unknown mechanism. 4,5 ABCA1 protein and its activity are also regulated by post-translational mechanisms. The turnover of ABCA1 protein is very rapid (Ϸ1 hour). Apolipoprotein A-I (apoAI) treatment of cells decreases the turnover of ABCA1, 6 whereas free cholesterol loading in macrophages lowers ABCA1 protein levels and activity by increasing ABCA1 degradation. 7 ABCA1 turnover appears to be regulated by several independent phosphorylation mechanisms, because apoAI-mediated stabilization of ABCA1 has been reported to be associated with both increased and decreased phosphorylation. 6, 8, 9 Specific dephosphorylation of a PEST sequence in ABCA1 blocks ABCA1 degradation by calpain and leads to an increase in cell-surface ABCA1. 9, 10 In contrast, unsaturated fatty acids markedly inhibit ABCA1-mediated cholesterol efflux to apoAI in macrophages by increasing ABCA1 turnover and subsequently decreasing cell-surface ABCA1 and apoAI binding to cells. 11 Cyclosporin A (CsA) is a strong immunosuppressant known to be a substrate for, and a noncompetitive inhibitor of, P-glycoprotein (P-gp), which is itself an ABC transporter (ABCB1). 12 Several studies have implicated P-gp in cellular cholesterol metabolism and trafficking. [13] [14] [15] In rat astrocytes, Ito et al have reported that apoAI induces translocation of cholesterol and phospholipids to the cytosol and that these reactions are suppressed by CsA. 16 Thus, we initiated a series of studies to determine whether CsA alters ABCA1 activity. In the current study, we provide evidence that CsA is a potent inhibitor of ABCA1 and that CsA reduces ABCA1 turnover and increases total and cell-surface ABCA1 in the RAW264.7 cells. In contrast, CsA strongly decreases apoAI uptake, resecretion, and degradation. Furthermore, CsA reduces Original
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Methods

Cell Culture and Lipid Efflux Assays
Cells were grown at 37°C in 5% CO 2 in Dulbecco modified Eagle medium (DMEM), or RPMI medium for THP1 cells, supplemented with 10% fetal bovine serum and penicillin streptomycin. Lipid efflux to apoAI (Biodesign, Saco, Me) or methyl-␤-cyclodextrin (Sigma) from cholesterol-loaded RAW264.7 cells was performed as previously described, 19, 20 with specific modifications for different cell lines mentioned in the figure legends. The percentage of cholesterol or choline phospholipid (PL) efflux was calculated as 100ϫ(medium dpm)/(medium dpmϩcell dpm).
Total and Cell-surface ABCA1 Quantification
RAW264.7 cells were grown in 100 mm 2 dishes (surface biotinylation) or 6-well plates (total ABCA1 content) to 80% confluence and incubated in DMEM supplemented with 50 mmol/L glucose, 2 mmol/L glutamine, and 0.2% bovine serum albumin (DME glutamine glucose BSA) in the presence or absence of 0.3 mmol/L 8Br-cAMP for 16 to 24 hours. Cells were treated for an additional 4 hours with or without 10 mol/L CsA (Sigma). To measure cell-surface ABCA1, plasma membrane proteins were purified via cell-surface biotinylation. Cells were incubated for 30 minutes on ice with phosphate-buffered saline (PBS) containing 1 mg/mL sulfo-NHS-biotin (Pierce). The PBS-washed cell pellet was lysed in 500 L of lysis buffer (2 mmol/L EDTA, 25 mmol/L Tris-Phosphate pH 7.8, 1% Triton X-100, and 10% protease inhibitor). After discarding the nuclear pellet, the protein concentration was determined using the micro BCA protein assay (Pierce). Analysis of total ABCA1 protein content was performed by Western blot using 20 g of cell protein. Cell-surface ABCA1 was determined by purifying biotinylated proteins by overnight incubation of 250 g of cell protein with 75 L of UltraLink Plus Immobilized Streptavidin gel (Pierce) at 4°C on a platform shaker in a final volume of 200 L in PBS. The bound protein samples were run on NuPAGE 3% to 8% Tris-Acetate Gels (Invitrogen) and transferred onto polyvinylidene fluoride membranes (Invitrogen). Blots were incubated sequentially with 1:500 rabbit polyclonal antibody raised against ABCA1 (provided by Dr M.R. Hayden) and 1:10 000 horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (Biorad). The signal was detected with an enhanced chemiluminescent substrate (Pierce) and direct chemiluminescent quantification was performed using a Biorad Chemi Doc system.
ABCA1 Turnover Assay
After 16 to 24 hours of incubation with DGGB containing 0.3 mmol/L 8Br-cAMP, RAW264.7 cells were washed with PBS and treated for the indicated incubation time with 100 g/mL cycloheximide (Sigma) and 0.3 mmol/L 8Br-cAMP in the presence or absence of 10 mol/L CsA. Then, total ABCA1 protein was analyzed by Western blot as described.
ABCA1 Cellular Localization
ABCA1-green fluorescent protein (GFP) stably transfected HEK293 20 were plated onto collagen-coated 4-chamber tissue culture glass slides (BD Falcon) at a density of 100 000 cells per chamber. After 24 hours of growth, cells were incubated for 4 hours at 37°C in the presence or absence of 10 mol/L CsA. The medium was removed and cells were washed 4 times with PBS, fixed with 10% phosphate-buffered formalin, and stained with 4Ј, 6-diamidino-2-phenylindole (DAPI, Vector Laboratories). Confocal microscopy was performed with a 63ϫ oil-immersion lens.
ApoAI Uptake, Degradation, and Resecretion Assay
Radiolabeling of 140 g of human ApoAI (specific activity 3620 cpm/ng) and assay of [ 125 I]apoAI uptake, degradation, and resecretion were performed as previously described. 21 Uptake of Alexa568-labeled apoAI, processing, fixation, and DAPI counterstaining were as previously described, 19 with the following modifications: an N-terminal His tagged ApoAI V93C substitution was created and purified by standard methods 22 and labeled with Alexa 568 Maleimide (Molecular Probes). All photographs were taken at identical exposure settings with DAPI and TRITC filter cubes using a 100ϫ oil-immersion lens.
CsA Injection and Plasma Lipid Analyses in C57BL/6 Mice
A pharmaceutical CsA solution (Bedford Laboratories) and vehicle (Cremophor EL; Sigma) were diluted in 0.9% sodium chloride before injection in mice. Ten male C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor, Me) and fed with a chow diet during the study. At 14 weeks of age, 100 L of blood was collected by retro-orbital puncture under light isoflurane anesthesia after a 5-hour daytime fast. Animals were then injected intraperitoneally daily for 6 days with either 50 mg/kg CsA (treated group, nϭ5) or vehicle (control group, nϭ5). After the last injection on day 6, 100 L of blood was collected by retro-orbital puncture under light isoflurane anesthesia after a 5-hour daytime fast. Plasma lipoprotein profiles of individual mice were determined by fast protein liquid chromatography of 10-L aliquots on twin Superose 6 columns with continuous online detection of cholesterol in the eluant. 23 HDL cholesterol levels were calculated from the area under the HDL peak compared with a standard curve constructed with human low-density lipoprotein chromatographed under the same conditions.
Statistics
Data are shown as meanϮSD. Comparison of 2 groups was performed by a 2-tailed t test, and comparison of 3 or more groups was performed by ANOVA with Newman-Keuls post-test. All statistics were performed using Prism software from GraphPad (San Diego, Calif).
Results
CsA Inhibits ABCA1-Mediated Lipid Efflux
A recent study has reported that apoAI induces translocation of free cholesterol (FC) and PL to an intracellular site in rat astrocytes and that this translocation is suppressed by CsA. 16 This observation suggests that CsA might inhibit ABCA1 activity, because FC and PL efflux to apoAI are mediated by ABCA1. To address this, we examined the effects of CsA on lipid efflux in RAW264.7 cells, a murine macrophage cell line in which cAMP analogues lead to Ϸ50-fold induction of ABCA1 mRNA and a robust induction of FC and PL efflux to apoAI. 5 We first analyzed the effect of CsA on FC efflux from RAW264.7 cells to methyl-␤-cyclodextrin, which strips FC from the plasma membrane, and when used in moderate doses for short time periods it can be used as an indicator of plasma membrane FC content. 19 We observed that 10 mol/L CsA, added 2 hours before the efflux period, and again during the 30-minute efflux period, did not affect FC efflux to methyl-␤-cyclodextrin, indicating that CsA did not alter the FC content in plasma membrane in RAW264.7 cells ( Figure  1A ). In contrast, 10 mol/L CsA led to an almost complete inhibition of 8Br-cAMP-induced ABCA1-mediated FC and PL efflux to apoAI, when added during the 4-hour lipid efflux period (Figure 1B and 1C; PϽ0.001) . Thus, CsA appeared to be a very potent inhibitor of ABCA1 in RAW264.7 cells. In a dose-response experiment, we calculated the IC 50 for CsA inhibition of ABCA1-mediated FC efflux as being 5.1 mol/L in RAW264.7 cells (data not shown). To assess whether CsA inhibition of cholesterol efflux might be mediated by P-gp inhibition, we tested 2 other P-gp inhibitors, verapamil and ketoconazole, and neither inhibited cholesterol efflux from ABCA1-induced RAW cells (data not shown). In a separate experiment using 8Br-cAMP-treated RAW264.7 cells, we examined the effect of a 2-hour 10 mol/L CsA pretreatment on the time course of FC efflux after washout of the CsA. As shown in Figure 1D , the time course of FC efflux to apoAI in CsA-pretreated cells was similar to that in nonpretreated cells. Thus, FC efflux to apoAI is fully and rapidly restored when CsA was removed from the culture medium, suggesting that CsA did not drastically reduce ABCA1 levels and that ABCA1 inhibition by CsA may be post-transcriptional.
To examine the species specificity of ABCA1 inhibition by CsA, we induced ABCA1 in differentiated human macrophage THP-1 cells with 22-hydroxy cholesterol and 9-cis retinoic acid. Similar to what we observed in RAW264.7 cells, the addition of 10 mol/L CsA in the medium during the 4-hour chase period significantly reduced FC efflux to apoAI in THP-1 cells (Figure 2 ; PϽ0.001). We also observed CsA inhibition of FC efflux to apoAI in mouse J774 macrophages and rat McA-RH7777 hepatocytes (data not shown). Thus, CsA inhibition of ABCA1 activity is not cell typespecific or species-specific.
CsA Increases Cell-surface ABCA1 and Decreases Its Turnover
Total and cell-surface ABCA1 were measured as described in the Methods section to determine whether ABCA1 inhibition by CsA results from a decrease of ABCA1 levels or an alteration of ABCA1 trafficking. As previously shown, 8Br-cAMP treatment of RAW267.4 cells induced total ABCA1 protein, which was increased an additional 33% (PϽ0.05) by the 4-hour treatment with 10 mol/L CsA ( Figure 3A ). More strikingly, the 4-hour CsA treatment led to a significant 2-fold increase in cell-surface ABCA1 (PϽ0.05). To confirm this CsA inhibition of ABCA1 is not species-specific. THP-1 cells were differentiated into macrophages with 100 ng/mL phorbol 12-myristate 13-acetate (PMA), cholesterol loaded with 50 g/mL acetylated LDL for 24 hours, and pretreated in the presence or absence of 4 g/mL 22-hydroxy-cholesterol and 1 mol/L 9-cis retinoic acid for 16 hours to induce ABCA1. Cholesterol efflux to 3 g/mL apoAI from cells was assayed in the presence or absence of 10 mol/L CsA for 4 hours at 37°C, nϭ3; *PϽ0.01, **PϽ0.001 compared with cells not treated with ABCA1 inducers, #PϽ0.001 compared with ABCA1-induced cells.
result, we analyzed the effect of CsA on the ABCA1 distribution in ABCA1-GFP stably transfected HEK293 cells. 20 As shown in the Figure 3B (left), and as previously reported, 24 ABCA1 is mainly localized in intracellular vesicles and at the cell surface. The 4-hour treatment with 10 mol/L CsA led to an apparent increase in ABCA1 at the plasma membrane ( Figure 3B, right) , confirming the results of the cell-surface biotinylation experiments. Thus, ABCA1 inhibition by CsA is not caused by a reduction of ABCA1 levels but instead it is associated with an increase of cellsurface ABCA1.
To address the possibility that the CsA-mediated ABCA1 immobilization at the plasma membrane affects ABCA1 turnover, RAW264.7 cells were stimulated with 8Br-cAMP and incubated with cycloheximide to inhibit protein synthesis in the presence or absence of CsA. Analysis of remaining cellular ABCA1 by Western blot showed that ABCA1 turnover was substantially slower in the CsA-treated cells with an ABCA1 half-life of 2.6 hours compared with 0.9 hours in the control-treated cells (Figure 4 ).
CsA Inhibits ApoAI Uptake
To elucidate the mechanism by which CsA inhibits ABCA1-mediated FC and PL to apoAI, we tested the possibility that CsA could affect apoAI trafficking in RAW264.7 cells. To address this, apoAI uptake, resecretion, and degradation were assayed by the incubation of RAW264. 7 (Figure 5A ), thus confirming our earlier observations. 21 Interestingly, these cAMP inductions were strongly reduced by the 10 mol/L CsA treatment (Ϫ79.6% and Ϫ75.2%, Ϫ90%, respectively; PϽ0.001). Thus, ABCA1 inhibition by CsA is accompanied by alterations in apoAI endocytosis, resecretion, and degradation by RAW264.7 cells. This result was confirmed by the use of fluorescently labeled apoAI. Cell uptake of apoAI, in a pattern consistent with endocytosis, was stimulated by 8Br-cAMP induction of ABCA1, as we and others have previously demonstrated. 20, 25 This uptake was reduced to background levels by CsA ( Figure 5B ).
CsA Reduces HDL Cholesterol Levels in Mice
Inactivating ABCA1 mutations lead to severe HDL deficiency in humans and mice. If ABCA1 inhibition by CsA occurs in vivo, then one would expect that CsA would reduce plasma HDL levels. To address this, C57BL/6 mice were injected intraperitoneally with 50 mg/kg per day CsA for 6 days and plasma HDL cholesterol levels were analyzed before and after treatment by fast protein liquid chromatography. No differences in the body weights were detected in the control and treated animals before and after the study. As shown in Figure 6 , a 6-day treatment with 50 mg/kg per day CsA induced a Ϸ33% (PϽ0.01) decrease of plasma HDL cholesterol levels in treated mice (nϭ5), whereas injection of vehicle in control mice (nϭ5) did not induce any significant changes. These findings suggest that CsA can inhibit ABCA1 activity in vivo.
Discussion
In this study, we report that CsA acts as a strong inhibitor of ABCA1 with CsA leading to increased ABCA1 at the plasma membrane and reduced apoAI uptake, resecretion, and degradation. Several inhibitors known to affect various ABC transporters have been demonstrated to inhibit ABCA1-mediated FC efflux to apoAI. Glyburide inhibits ABCA1-mediated lipid efflux in RAW264.7 cells, 19 smooth muscle cells, 26 and HEK293 cells, in which it was shown to abolish apoAI binding to the cells and cross-linking to ABCA1. 27 Vanadate and its derivatives have been reported to either inhibit 19, 26 or have no significant effect 27 on ABCA1-mediated lipid efflux to apoAI. Compared with those compounds, we show that CsA, a substrate and inhibitor of the ABC transporter family member P-gp (ABCB1), is a very potent inhibitor of ABCA1 activity, with a 10 mol/L dose leading to 90% inhibition of both FC and PL efflux to apoAI, whereas we previously demonstrated that 1 mmol/L glyburide or vanadate were required to observe a similar inhibitory effect. 19 Probucol also acts as an ABCA1 inhibitor, with half maximal inhibition of Ϸ20 mol/L. 28 We found that the IC 50 for ABCA1 inhibition by CsA was Ϸ5 mol/L; therefore, CsA appears to be the most potent ABCA1 inhibitor described. The mechanism by which CsA inhibits ABCA1 provides new clues in the understanding of the ABCA1-mediated lipid efflux to apolipoprotein acceptors. It has previously been shown that treatments that increase ABCA1 levels by decreasing its degradation are associated with increased lipid efflux to apoAI. 29 -31 For example, ceramides increase cellsurface ABCA1 and ABCA1-mediated FC efflux in CHO cells. 31 ABCA1 interaction with apoAI or synthetic amphipathic helical peptides prevents ABCA1 degradation and leads to the increase of ABCA1 levels and lipid efflux activity. 6,8 -10,30 Phospholipid transfer protein can also bind to ABCA1 and decrease its turnover. 32 ABCA1 contains a C-terminal PDZ-binding domain, and cotransfection of ABCA1 with the PDZ protein ␣1-syntrophin markedly decreases ABCA1 turnover. 33 In contrast, unsaturated fatty acids inhibit ABCA1-mediated FC efflux to apoAI in macrophages by increasing ABCA1 turnover and decreasing cell-surface ABCA1. 11 FC loading of macrophages also increases ABCA1 turnover, which can be blocked by a proteosome inhibitor. 7 Surprisingly, CsA inhibition of ABCA1 was accompanied by a decrease of ABCA1 turnover and a subsequent increase of total and cell-surface ABCA1 in RAW264.7 cells. This is similar to what was recently observed by the inhibition of human fibroblast ABCA1 by probucol. 28 Although we did not specifically assess the effect . CsA treatment reduces plasma HDL cholesterol levels in mice. C57BL/6 mice were injected intraperitoneally once per day with either 50 mg/kg CsA (nϭ5) or vehicle (nϭ5). Fasted blood samples were collected before the first injection on day 1 (D1) and after the last injection on day 6 (D6), and plasma HDL cholesterol levels were assayed by fast protein liquid chromatography.
of CsA on ABCA1 mRNA, we observed that the removal of CsA from the medium fully and rapidly restored FC efflux to apoAI in RAW264.7 cells, a result that supports a posttranscriptional mechanism of ABCA1 inhibition. In agreement with this hypothesis, Jin et al have reported that mRNA expression of ABCA1 was not altered by CsA in THP-1 cells. 34 Previous studies have suggested that the localization of ABCA1 at the plasma membrane favors the interaction with apoAI and thus stimulates lipid efflux to apoAI. 4, 24 However, our finding provides evidence that an increase of ABCA1 at the cell surface is not necessarily associated with a stimulation of lipid efflux, suggesting that a more complex regulatory mechanism occurs. We previously proposed and found evidence to support the hypothesis that ABCA1-dependent FC efflux to apoAI involves endocytosis and resecretion of apoAI. 19 -21 Inhibitors of endocytosis reduced FC efflux to apoAI. Induction of ABCA1 led to markedly increased levels of cellular binding, uptake, and resecretion of apoAI, and this apoAI uptake occurred in coated pits. Moreover, cholesterol efflux to apoAI and apoAI cellular uptake and degradation requires extracellular Ca 2ϩ . 21 In cells stably transfected with an ABCA1-GFP fusion expression vector, ABCA1 and apoAI were colocalized in intracellular vesicles at 37°C. 20 The time course and temperature dependence of ABCA1-mediated lipid efflux to apoAI are also consistent with a role for endocytosis in this process. 19 The retroendocytosis hypothesis has been supported by data from other laboratories that demonstrated bidirectional transport of ABCA1 between the plasma membrane and intracellular vesicles, 24 and that intracellular pools of cholesterol constituted the major cholesterol source for ABCA1-mediated FC efflux to apoAI. 35, 36 In this study, we observed that the CsA inhibition of ABCA1 is accompanied by a strong reduction of apoAI uptake, resecretion, and degradation in RAW264.7 cells; thus, despite the increase of total and cell-surface ABCA1, CsA is able to inhibit ABCA1-mediated FC efflux by altering ABCA1 and apoAI trafficking. Thus, CsA could result in plasma membrane-bound ABCA1 that cannot bind to apoAI or ABCA1 that can bind apoAI but cannot mediate endocytosis and lipid efflux, and we were unable to distinguish between these possibilities because CsA led to ABCA1-independent binding of apoAI to cells at 4°C (data not shown).
We did not investigate the mechanism by which CsA sequesters ABCA1 to the plasma membrane; however, CsA has been demonstrated to directly bind to P-gp, 37, 38 and by analogy we speculate that CsA may bind directly to ABCA1 and alter its activity and cellular trafficking. Of course, other mechanisms are also possible, including calcineurin-mediated effects resulting in changes in ABCA1 phosphorylation or other post-translational modifications. Because CsA sequesters ABCA1 at the plasma membrane and decreases ABCA1 turnover, we suggest that ABCA1 turnover is in part regulated by bidirectional vesicular trafficking of ABCA1.
CsA treatment of transplantation patients is associated with an increased incidence of dyslipidemia, a risk factor for cardiovascular disease. 39 We observed that a 6-day CsA treatment markedly reduced plasma HDL cholesterol levels in chow diet-fed C57BL/6 mice, a result in agreement with decreased plasma HDL cholesterol and apoAI levels observed in some studies of transplantation patients. 17, 18 Because the liver is the major source of plasma HDL in mice, 1,2 the observed in vivo effect of CsA on HDL is probably caused by hepatic inhibition of ABCA1, consistent with ABCA1 inhibition we observed in McA-RH7777 rat hepatocytes. However, a previous study did not observe a CsAmediated reduction of plasma HDL cholesterol levels in C57BL/6 mice that were fed an atherogenic diet. 40 The lack of response to CsA in this study might be caused by the already low levels of HDL in response to the high-cholesterol cholate-containing diet, or the extended length of treatment (Ն135 days), which could allow compensatory mechanisms to overcome the CsA effects on HDL. 40 In conclusion, ABCA1 inhibition by CsA in vivo could contribute in part to the appearance of the dyslipidemia frequently observed in transplantation patients; thus, CsA therapy may have unintended atherogenic consequences.
